{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:23:49Z","timestamp":1779215029350,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31313-6","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:19:45Z","timestamp":1767791985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model"],"prefix":"10.1038","volume":"16","author":[{"given":"H\u00e9ctor","family":"Frayde-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Chimal-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Pulido-Capiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mu\u00f1oz-Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Galindo-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Vique-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Gabriela","family":"Leija-Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"D\u00edaz-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo A.","family":"Madero-Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"Ramos-Ibarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"31313_CR1","doi-asserted-by":"publisher","unstructured":"\u0141ukasiewicz, S. et al. Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014An updated review. Cancers 13. https:\/\/doi.org\/10.3390\/cancers13174287 Preprint at (2021).","DOI":"10.3390\/cancers13174287"},{"key":"31313_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"31313_CR3","doi-asserted-by":"publisher","unstructured":"Kunc, M., Biernat, W. & Senkus-Konefka, E. Estrogen receptor-negative progesterone receptor-positive breast cancer \u2013 Nobody\u2019s land or just an artifact? Cancer Treatment Reviews vol. 67 78\u201387 Preprint at (2018). https:\/\/doi.org\/10.1016\/j.ctrv.2018.05.005","DOI":"10.1016\/j.ctrv.2018.05.005"},{"key":"31313_CR4","doi-asserted-by":"publisher","unstructured":"Kumar, P. & Aggarwal, R. An overview of triple-negative breast cancer. Archives of Gynecology and Obstetrics vol. 293 247\u2013269 Preprint at (2016). https:\/\/doi.org\/10.1007\/s00404-015-3859-y","DOI":"10.1007\/s00404-015-3859-y"},{"key":"31313_CR5","doi-asserted-by":"publisher","unstructured":"Yin, L., Duan, J. J., Bian, X. W. & Yu, S. C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research 22 https:\/\/doi.org\/10.1186\/s13058-020-01296-5 Preprint at (2020).","DOI":"10.1186\/s13058-020-01296-5"},{"key":"31313_CR6","doi-asserted-by":"publisher","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144 646\u2013674 https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 Preprint at (2011).","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"31313_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12032-023-02138-y","volume":"40","author":"S Kannampuzha","year":"2023","unstructured":"Kannampuzha, S. & Gopalakrishnan, A. V. Cancer chemoresistance and its mechanisms: associated molecular factors and its regulatory role. Med. Oncol. 40, 264 (2023).","journal-title":"Med. Oncol."},{"key":"31313_CR8","doi-asserted-by":"publisher","unstructured":"Palomeras, S., Ruiz-Mart\u00ednez, S. & Puig, T. Targeting breast cancer stem cells to overcome treatment resistance. Molecules vol. 23 Preprint at. https:\/\/doi.org\/10.3390\/molecules23092193 (2018).","DOI":"10.3390\/molecules23092193"},{"key":"31313_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/2211738507666190122111224","volume":"7","author":"FA Fisusi","year":"2019","unstructured":"Fisusi, F. A. & Akala, E. O. Drug combinations in breast cancer therapy. Pharm. Nanotechnol. 7, 3\u201323 (2019).","journal-title":"Pharm. Nanotechnol"},{"key":"31313_CR10","doi-asserted-by":"publisher","unstructured":"Bai, X., Ni, J., Beretov, J., Graham, P. & Li, Y. Triple-negative breast cancer therapeutic resistance: Where is the Achilles\u2019 heel? Cancer Letters vol. 497 100\u2013111 Preprint at. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.016 (2021).","DOI":"10.1016\/j.canlet.2020.10.016"},{"key":"31313_CR11","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019 Aug 22;8(9):957. doi: 10.3390\/cells8090957","DOI":"10.3390\/cells8090957"},{"key":"31313_CR12","doi-asserted-by":"publisher","unstructured":"An, J., Peng, C., Tang, H., Liu, X. & Peng, F. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. International Journal of Molecular Sciences vol. 22 Preprint at. https:\/\/doi.org\/10.3390\/ijms22179644(2021).","DOI":"10.3390\/ijms22179644"},{"key":"31313_CR13","doi-asserted-by":"publisher","unstructured":"Gonzalez-Ortiz, A., Galindo-Hernandez, O., Hernandez-Acevedo, G. N., Hurtado-Ureta, G. & Garcia-Gonzalez, V. Impact of cholesterol-pathways on breast cancer development, a metabolic landscape. Journal of Cancer vol. 12 4307\u20134321 Preprint at. https:\/\/doi.org\/10.7150\/jca.54637 (2021).","DOI":"10.7150\/jca.54637"},{"key":"31313_CR14","doi-asserted-by":"publisher","unstructured":"Malka-Mahieu, H., Newman, M., D\u00e9saubry, L., Robert, C. & Vagner, S. Molecular pathways: The eIF4F translation initiation complex-newopportunities for cancer treatment. Clinical Cancer Research vol. 23 21\u201325 Preprint at. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2362 (2017).","DOI":"10.1158\/1078-0432.CCR-14-2362"},{"key":"31313_CR15","doi-asserted-by":"publisher","unstructured":"Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discovery vol. 12 31\u201346 Preprint at. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059 (2022).","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"31313_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/bs.apcsb.2022.05.011","volume":"132","author":"A Mu\u00f1oz-Ayala","year":"2022","unstructured":"Mu\u00f1oz-Ayala, A. & Chimal-Vega, B. Garc\u00eda-Gonz\u00e1lez, V. Translation initiation and its relationship with metabolic mechanisms in cancer development, progression and chemoresistance. Adv. Protein Chem. Struct. Biol. 132, 111\u2013141 (2022).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"31313_CR17","doi-asserted-by":"publisher","unstructured":"Romagnoli, A. et al. Control of the eIF4E activity: structural insights and pharmacological implications. Cellular and Molecular Life Sciences vol. 78 6869\u20136885 Preprint at. https:\/\/doi.org\/10.1007\/s00018-021-03938-z (2021).","DOI":"10.1007\/s00018-021-03938-z"},{"key":"31313_CR18","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.molcel.2015.01.017","volume":"57","author":"D Peter","year":"2015","unstructured":"Peter, D. et al. Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. Mol. Cell. 57, 1074\u20131087 (2015).","journal-title":"Mol. Cell."},{"key":"31313_CR19","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.2174\/0929867329666220224112042","volume":"29","author":"C Maracci","year":"2022","unstructured":"Maracci, C. et al. The mTOR\/4E-BP1\/eIF4E signalling pathway as a source of cancer drug targets. Curr. Med. Chem. 29, 3501\u20133529 (2022).","journal-title":"Curr. Med. Chem."},{"key":"31313_CR20","doi-asserted-by":"publisher","first-page":"Preprintathttps","DOI":"10.1016\/j.cellsig.2020.109689","volume":"73","author":"X Yang","year":"2020","unstructured":"Yang, X., Zhong, W. & Cao, R. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer. Cell. Signal. 73, Preprintathttpsdoiorg101016jcellsig2020109689 (2020).","journal-title":"Cell. Signal."},{"key":"31313_CR21","doi-asserted-by":"crossref","unstructured":"Zheng, J., Li, X., Zhang, C. & Zhang, Y. eIF4E Overexpression Is Associated with Poor Prognoses of Ovarian Cancer. Analytical Cellular Pathology 2020. (2020).","DOI":"10.1155\/2020\/8984526"},{"key":"31313_CR22","doi-asserted-by":"crossref","unstructured":"Tang, Y. et al. Overexpression of p-4EBP1 associates with peIF4E and predicts poor prognosis for non-small cell lung cancer patients with resection. PLoS One 17(6): e0265465. https:\/\/ doi.org\/10.1371\/journal.pone.0265465 (2022).","DOI":"10.1371\/journal.pone.0265465"},{"key":"31313_CR23","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1128\/MCB.00448-10","volume":"30","author":"M Shveygert","year":"2010","unstructured":"Shveygert, M., Kaiser, C., Bradrick, S. S. & Gromeier, M. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by Mitogen-Activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol. Cell. Biol. 30, 5160\u20135167 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"31313_CR24","doi-asserted-by":"crossref","unstructured":"Lee, S. C. et al. G-Quadruplex in the NRF2 mRNA 5\u2032 untranslated region regulates de Novo NRF2 protein translation under oxidative stress. Mol Cell. Biol 37(1), e00122-16. https:\/\/doi.org\/10.1128\/MCB.00122-16 (2017).","DOI":"10.1128\/MCB.00122-16"},{"key":"31313_CR25","doi-asserted-by":"publisher","unstructured":"Ma, Q. Role of Nrf2 in oxidative stress and toxicity. Annual Review of Pharmacology and Toxicology vol. 53 401\u2013426 Preprint at (2013). https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140320","DOI":"10.1146\/annurev-pharmtox-011112-140320"},{"key":"31313_CR26","doi-asserted-by":"publisher","unstructured":"Almeida Lima, K. et al. Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil. Biomedicines vol. 11 Preprint at. https:\/\/doi.org\/10.3390\/biomedicines11041081 (2023).","DOI":"10.3390\/biomedicines11041081"},{"key":"31313_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123609","volume":"12","author":"H Robertson","year":"2020","unstructured":"Robertson, H., Dinkova-Kostova, A. T. & Hayes, J. D. Nrf2 and the ambiguous consequences of its activation during initiation and the subsequent stages of tumourigenesis. Cancers (Basel). 12, 1\u201348 (2020).","journal-title":"Cancers (Basel)"},{"key":"31313_CR28","doi-asserted-by":"publisher","unstructured":"de la Rojo, M., Chapman, E. & Zhang, D. D. NRF2 and the Hallmarks of Cancer. Cancer Cell vol. 34 21\u201343 Preprint at. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.022 (2018).","DOI":"10.1016\/j.ccell.2018.03.022"},{"key":"31313_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102726","author":"S Adinolfi","year":"2023","unstructured":"Adinolfi, S. et al. The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biology Vol. https:\/\/doi.org\/10.1016\/j.redox.2023.102726 (2023). 63 Preprint at.","journal-title":"Redox Biology Vol"},{"key":"31313_CR30","doi-asserted-by":"publisher","unstructured":"Lin, T. Y., Cantley, L. C. & DeNicola, G. M. NRF2 rewires cellular metabolism to support the antioxidant Response. In A master regulator of oxidative Stress - The transcription factor Nrf2 (InTech, https:\/\/doi.org\/10.5772\/65141 (2016).","DOI":"10.5772\/65141"},{"key":"31313_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/00498254.2023.2264391","volume":"53","author":"K Piska","year":"2023","unstructured":"Piska, K. et al. Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance. Xenobiotica 53, 507\u2013514 (2023).","journal-title":"Xenobiotica"},{"key":"31313_CR32","doi-asserted-by":"publisher","first-page":"Preprintathttps","DOI":"10.1016\/j.ejmech.2022.114542","volume":"239","author":"K Engle","year":"2022","unstructured":"Engle, K. & Kumar, G. Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. Eur. J. Med. Chem. 239, Preprintathttpsdoiorg101016jejmech2022114542 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"31313_CR33","doi-asserted-by":"crossref","unstructured":"Ji, L. et al. Nrf2 pathway regulates Multidrug-Resistance-Associated protein 1 in small cell lung cancer. PLoS One 8(5), e63404. https:\/\/doi.org\/10.1371\/journal.pone.0063404 (2013).","DOI":"10.1371\/journal.pone.0063404"},{"key":"31313_CR34","doi-asserted-by":"publisher","unstructured":"Tang, Y. C. et al. How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy. Journal of Food and Drug Analysis vol. 31 387\u2013407 Preprint at. https:\/\/doi.org\/10.38212\/2224-6614.3463 (2023).","DOI":"10.38212\/2224-6614.3463"},{"key":"31313_CR35","doi-asserted-by":"crossref","unstructured":"Abd El-Aziz, Y. S., Spillane, A. J., Jansson, P. J. & Sahni, S. Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers. Biosci Rep 41(2):BSR20204092. doi:10.1042\/BSR20204092 (2021).","DOI":"10.1042\/BSR20204092"},{"key":"31313_CR36","doi-asserted-by":"crossref","unstructured":"Miodragovi\u0107, \u00d0. et al. Iodide analogs of arsenoplatins\u2014potential drug candidates for triple negative breast cancers. Molecules 26(17), 5421; https:\/\/doi.org\/10.3390\/molecules26175421 (2021).","DOI":"10.3390\/molecules26175421"},{"key":"31313_CR37","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Ortiz, A. et al. eIF4A\/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. Cells 11, (2022).","DOI":"10.3390\/cells11244069"},{"key":"31313_CR38","doi-asserted-by":"publisher","first-page":"122563","DOI":"10.1016\/j.lfs.2024.122563","volume":"345","author":"M Malekan","year":"2024","unstructured":"Malekan, M. et al. VEGF\/VEGFR axis and its signaling in melanoma: current knowledge toward therapeutic targeting agents and future perspectives. Life Sci. 345, 122563 (2024).","journal-title":"Life Sci."},{"key":"31313_CR39","doi-asserted-by":"crossref","unstructured":"Jiang, H. & Li, H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer 21(1), 149. https:\/\/doi.org\/10.1186\/s12885-021-07860-2 (2021).","DOI":"10.1186\/s12885-021-07860-2"},{"key":"31313_CR40","doi-asserted-by":"crossref","unstructured":"Blukacz, L. et al. Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC. Hepatol Commun 8(5), e0437. https:\/\/doi.org\/10.1097\/HC9.0000000000000437 (2024).","DOI":"10.1097\/HC9.0000000000000437"},{"key":"31313_CR41","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"GEPIA","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45. GEPIA, W98\u2013W102 (2017).","journal-title":"Nucleic Acids Res. 45"},{"key":"31313_CR42","doi-asserted-by":"crossref","unstructured":"Gy\u0151rffy, B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation 5(3), 100625. https:\/\/doi.org\/10.1016\/j.xinn.2024.100625 (2024).","DOI":"10.1016\/j.xinn.2024.100625"},{"key":"31313_CR43","doi-asserted-by":"crossref","unstructured":"Elefantova, K., Lakatos, B., Kubickova, J., Sulova, Z. & Breier, A. Detection of the mitochondrial membrane potential by the cationic dye JC-1 in l1210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter. Int J. Mol. Sci 19(7), 1985. https:\/\/doi.org\/10.3390\/ijms19071985 (2018).","DOI":"10.3390\/ijms19071985"},{"key":"31313_CR44","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Ayala, A. et al. Tamoxifen metabolites treatment promotes ER\u03b1\u2009+\u2009transition to triple negative phenotype in vitro, effects of LDL in chemoresistance. Biosci Rep 44(8), BSR20240444. https:\/\/doi.org\/10.1042\/BSR20240444 (2024).","DOI":"10.1042\/BSR20240444"},{"key":"31313_CR45","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/DDDT.S251144","volume":"14","author":"Y Harahap","year":"2020","unstructured":"Harahap, Y., Ardiningsih, P., Winarti, A. C. & Purwanto, D. J. Analysis of the doxorubicin and doxorubicinol in the plasma of breast cancer patients for monitoring the toxicity of doxorubicin. Drug Des. Devel Ther. 14, 3469\u20133475 (2020).","journal-title":"Drug Des. Devel Ther."},{"key":"31313_CR46","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Valencia, J. et al. Lapatinib-Resistant HER2\u2009+\u2009Breast cancer cells are associated with dysregulation of MAPK and p70S6K\/PDCD4 pathways and calcium Management, influence of Cryptotanshinone. Int J. Mol. Sci 26(8), 3763. https:\/\/doi.org\/10.3390\/ijms26083763 (2025).","DOI":"10.3390\/ijms26083763"},{"key":"31313_CR47","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.mam.2023.101205","volume":"93","author":"R Mattioli","year":"2023","unstructured":"Mattioli, R. et al. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Mol. Aspects Med. 93, 101205 (2023).","journal-title":"Mol. Aspects Med."},{"key":"31313_CR48","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won, K. A. & Spruck, C. Triple-negative breast cancer therapy: current and future perspectives. Int. J. Oncol. 57, 1245\u20131261 (2020).","journal-title":"Int. J. Oncol."},{"key":"31313_CR49","doi-asserted-by":"crossref","unstructured":"Paramanantham, A. et al. Doxorubicin-resistant Tnbc cells exhibit rapid growth with cancer stem cell-like properties and Emt phenotype, which can be transferred to parental cells through autocrine signaling. Int J. Mol. Sci 22(22), 12438. https:\/\/doi.org\/10.3390\/ijms222212438 (2021).","DOI":"10.3390\/ijms222212438"},{"key":"31313_CR50","doi-asserted-by":"crossref","unstructured":"Mohammed, S. et al. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src family non-receptor tyrosine kinases. Breast Cancer Research 23(1), 76. https:\/\/doi.org\/10.1186\/s13058-021-01452-5, (2021).","DOI":"10.1186\/s13058-021-01452-5"},{"key":"31313_CR51","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"31313_CR52","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.biopha.2018.05.062","volume":"104","author":"MR Sadeghi","year":"2018","unstructured":"Sadeghi, M. R. et al. Nrf2\/P\u2013glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer. Biomed. Pharmacotherapy. 104, 458\u2013464 (2018).","journal-title":"Biomed. Pharmacotherapy"},{"key":"31313_CR53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2174\/1568009617666171002144228","volume":"18","author":"S Sajadimajd","year":"2017","unstructured":"Sajadimajd, S. & Khazaei, M. Oxidative stress and cancer: the role of Nrf2. Curr. Cancer Drug Targets. 18, 538\u2013557 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"key":"31313_CR54","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Gonz\u00e1lez, V. et al. Ceramide metabolism balance, a multifaceted factor in critical steps of breast cancer development. International Journal of Molecular Sciences vol. 19 Preprint at. https:\/\/doi.org\/10.3390\/ijms19092527 (2018).","DOI":"10.3390\/ijms19092527"},{"key":"31313_CR55","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1097\/CAD.0000000000001074","volume":"32","author":"C Fang","year":"2021","unstructured":"Fang, C. et al. EIF4E-eIF4G complex Inhibition synergistically enhances the effect of Sorafenib in hepatocellular carcinoma. Anticancer Drugs. 32, 822\u2013828 (2021).","journal-title":"Anticancer Drugs"},{"key":"31313_CR56","doi-asserted-by":"crossref","unstructured":"Tan, J., Ye, J., Song, M., Zhou, M. & Hu, Y. Ribavirin augments doxorubicin\u2019s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem. Mol. Toxicol 32(1), 10.1002\/jbt.22007. https:\/\/doi.org\/10.1002\/jbt.22007 (2018).","DOI":"10.1002\/jbt.22007"},{"key":"31313_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.21873\/cgp.20408","volume":"20","author":"J Park","year":"2023","unstructured":"Park, J. et al. Using comparative proteomics to identify protein signatures in clear cell renal cell carcinoma. Cancer Genomics Proteom. 20, 592\u2013601 (2023).","journal-title":"Cancer Genomics Proteom."},{"key":"31313_CR58","doi-asserted-by":"crossref","unstructured":"dos Reis, S. B. et al. Mechanistic insights into the intracellular release of doxorubicin from pH-sensitive liposomes. Biomedicine Pharmacotherapy 134,110952. https:\/\/doi.org\/10.1016\/j.biopha.2020.110952 (2021).","DOI":"10.1016\/j.biopha.2020.110952"},{"key":"31313_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07512-6","author":"\u00cdSS de Amorim","year":"2024","unstructured":"de Amorim, \u00cd. S. S. et al. APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3\/7-mediated apoptosis. Breast Cancer Res. Treat. https:\/\/doi.org\/10.1007\/s10549-024-07512-6 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"31313_CR60","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12079-018-0490-2","volume":"13","author":"E Leal-Orta","year":"2019","unstructured":"Leal-Orta, E., Ramirez-Ricardo, J., Cortes-Reynosa, P., Galindo-Hernandez, O. & Salazar, E. P. Role of PI3K\/Akt on migration and invasion of MCF10A cells treated with extracellular vesicles from MDA-MB-231 cells stimulated with Linoleic acid. J. Cell. Commun. Signal. 13, 235\u2013244 (2019).","journal-title":"J. Cell. Commun. Signal."},{"key":"31313_CR61","doi-asserted-by":"crossref","unstructured":"Oregel-Cortez, M. I. et al. Resistin induces migration and invasion in PC3 prostate cancer cells: role of extracellular vesicles. Life 13(12), 2321. https:\/\/doi.org\/10.3390\/life13122321 (2023).","DOI":"10.3390\/life13122321"},{"key":"31313_CR62","doi-asserted-by":"crossref","unstructured":"Guevara-Olaya, L. et al. LDL Promotes Disorders in \u03b2-Cell Cholesterol Metabolism, Implications on Insulin Cellular Communication Mediated by EVs. Metabolites 12,(8), 754. https:\/\/doi.org\/10.3390\/metabo12080754 (2022).","DOI":"10.3390\/metabo12080754"},{"key":"31313_CR63","doi-asserted-by":"publisher","unstructured":"Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nature Genetics vol. 45 580\u2013585 Preprint at. https:\/\/doi.org\/10.1038\/ng.2653 (2013).","DOI":"10.1038\/ng.2653"},{"key":"31313_CR64","doi-asserted-by":"crossref","unstructured":"Ribeiro, J. V. et al. QwikMD - Integrative molecular dynamics toolkit for novices and experts. Sci Rep 6, 26536. https:\/\/doi.org\/10.1038\/srep26536 (2016).","DOI":"10.1038\/srep26536"},{"key":"31313_CR65","doi-asserted-by":"crossref","unstructured":"Phillips, J. C. et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. Journal Chem. Physics 153(4), 044130. https:\/\/doi.org\/10.1063\/5.0014475, (2020).","DOI":"10.1063\/5.0014475"},{"key":"31313_CR66","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/jcc.24829","volume":"38","author":"S Kim","year":"2017","unstructured":"Kim, S. et al. CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules. J. Comput. Chem. 38, 1879\u20131886 (2017).","journal-title":"J. Comput. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31313-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:00:39Z","timestamp":1768395639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31313-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31313"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31313-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1805"}}